Characterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody
-
Published:2021-08
Issue:8
Volume:110
Page:2904-2915
-
ISSN:0022-3549
-
Container-title:Journal of Pharmaceutical Sciences
-
language:en
-
Short-container-title:Journal of Pharmaceutical Sciences
Author:
Cao MingyanORCID,
Parthemore Conner,
Jiao YangORCID,
Korman SamuelORCID,
Aspelund Matthew,
Hunter Alan,
Kilby Greg,
Chen Xiaoyu
Subject
Pharmaceutical Science
Reference44 articles.
1. Mazor Y, Sachsenmeier KF, Yang C, et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. 2017;7(1):1–11.
2. Nie S, Wang Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. 2020;3(1):18–62.
3. Antibodies to watch in 2020;Kaplon;mAbs,2020
4. Expanding the boundaries of biotherapeutics with bispecific antibodies;Husain;BioDrugs,2018
5. “One, if by land, and two, if by sea”: bispecific antibodies join the revolution;Rader;Methods (San Diego, Calif.),2019
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献